title: High avidity CD8+ T cells are the initial population elicited following viral infection of the respiratory tract.
abstract: Following intranasal administration, the model paramyxovirus simian virus 5 (SV5) establishes an infection in the respiratory tract of mice, which is subsequently cleared by CD8+ T cells. In this study, we sought to understand the maturation of the antiviral immune response over time by assessing the functional avidity of the responding T cells and the expansion of immunodominant populations. Surprisingly, we determined that the initial response to Ag at day 3 (d3) in the mediastinal lymph node was exclusively high avidity. However, by d5 postinfection, low avidity cells were approximately 50% of the responding T cell population. Following secondary exposure to SV5, high avidity CD8+ T cells again are the exclusive cell type present at early times postinfection (d2). Similarly, high avidity cells were preferentially elicited at d3 following infection with the unrelated vaccinia virus. We also made the observation that the immunodominance profile has not been established at d3 postinfection with SV5. However, by d5 a clear immunodominance pattern arises and is permanently maintained. These data indicate that high avidity cells are the predominant population responding at early times postinfection following respiratory infection with SV5 or vaccinia virus. However, as the response progresses, low avidity cells are activated/expanded to a greater extent compared with high avidity cells.
authors.affiliation: Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Gray
authors.forename: Griffith D
authors.initials: GD
authors.lastname: Parks
authors.forename: Martha A
authors.initials: MA
authors.lastname: Alexander-Miller
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology / Q000821:virology; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D007114:Immunization; D007117:Immunization, Secondary; D016056:Immunodominant Epitopes / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000473:pathology / Q000821:virology; D008198:Lymph Nodes / Q000276:immunology / Q000821:virology; D008213:Lymphocyte Activation; D008482:Mediastinum; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D012141:Respiratory Tract Infections / Q000276:immunology* / Q000821:virology*; D018108:Respirovirus / Q000276:immunology; D010253:Respirovirus Infections / Q000276:immunology* / Q000821:virology; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000821:virology; D014407:Tumor Cells, Cultured; D014615:Vaccinia / Q000276:immunology / Q000821:virology; D014764:Viral Proteins / Q000276:immunology
chemical_list: D016056:Immunodominant Epitopes; D014764:Viral Proteins